Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 0.310% compared to yesterday.
The stock is one of the favorites of our community with 34 Buy predictions and 1 Sell predictions.
With a target price of 28 € there is a positive potential of 44.18% for Acadia Pharmaceuticals compared to the current price of 19.42 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.310% | 1.675% | 4.634% | 25.900% | -16.401% | 8.540% | -14.166% |
| United Therapeutics | 1.490% | 13.960% | 17.057% | 66.631% | 9.853% | 124.164% | 250.299% |
| Iovance Biotherapeutics Inc. | -1.520% | -21.720% | 59.719% | 6.635% | 46.016% | -42.790% | -88.067% |
| Ligand Pharmaceuticals | -6.250% | 1.667% | 16.561% | 69.444% | 10.241% | 191.773% | 33.091% |
Comments
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat